Q517--Contingency Chemotherapy Compounding Services Louis A Johnson VA Medical Center
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Louis A. Johnson VA Medical Center (LAJVAMC) is conducting a Sources Sought to identify contractors capable of providing contingency hazardous chemotherapy compounding services. This market research aims to find a backup solution for the VA Clarksburg Inpatient Pharmacy in the event of an IV room shutdown. Responses are due March 25, 2026, at 3:00 p.m. EST.
Purpose & Scope
The LAJVAMC Inpatient Pharmacy requires a contingency contractor to handle hazardous compounding, as it currently has only one IV room. This effort is crucial to ensure continuous service if the primary IV room becomes unavailable. The scope of work includes providing all necessary chemotherapy agents, IV tubing, closed system drug transfer devices, and other items. The contractor will aseptically compound patient-specific hazardous chemotherapy agents, supply all drugs, and manage order reception via secure VA network or fax, with confirmation by phone or email. Transport of compounded orders must be via courier or overnight mail to ensure timely receipt before infusion, with shipping costs included.
Key Requirements & Performance Standards
Services must be performed at an FDA 503A compliant facility and adhere to all state and federal laws, including USP 797 and USP 800 for compounding, labeling, and expiration dating. Contractors must provide current and future certification reports for sterile compounding areas and hoods, along with action plans for any deficiencies. A contingency backup plan for facility disruptions is also required. The anticipated period of performance is a Base Year (August 27, 2026 – August 26, 2027) plus four Option Years, extending through August 26, 2031.
Contract & Timeline
- Opportunity Type: Sources Sought / Market Research
- NAICS Code: 456110 (Pharmacy Services)
- Place of Performance: Louis A. Johnson VA Medical Center, Clarksburg, WV
- Response Due: March 25, 2026, 3:00 p.m. EST
- Published Date: March 9, 2026
Eligibility & Submission
This is a market research tool. If a small business is interested, they must be capable of providing at least 51 percent of the services rendered. Interested businesses should submit a capability statement including their business name, type, socio-economic status, point of contact, GSA contract number (if applicable), and a summary of relevant experience. Responses must be submitted via email only to Sylvia.Honesty@va.gov.
Additional Notes
This notice is for informational and planning purposes only and does not constitute a solicitation. Responses are voluntary and will assist the Government in developing its acquisition strategy. A formal solicitation is not currently available, and all interested parties will need to respond separately to any future solicitation. The VA assumes no responsibility for costs incurred in preparing responses.